ClinicalTrials.gg
CompletedNCT00828204Updated Jun 3, 2014Results posted

Evaluate the Safe and Effective Use of the Avonex® Single-Use Autoinjector in Multiple Sclerosis Subjects

A Phase 3 interventional study of single-use autoinjector with a prefilled liquid Avonex syringe and Avonex prefilled syringe via manual IM injection in Multiple Sclerosis, sponsored by Biogen. Completed at 16 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-06-03.

Sponsored by Biogen · Phase 3 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
95
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 34 studies testing Interferon beta-1a in Multiple Sclerosis — none open to participants now, none under way, none of them phase 3. Interferon beta-1a · Multiple Sclerosis.

Enrollment
16th of 34
95 · median 85
Started
2009
the only one that year
Phase 3
7 of 34
none open now
Registered
17th of 34
by date
Lead sponsor
15 of 34
Biogen

Among the 34 studies testing Interferon beta-1a in Multiple Sclerosis, this one is the 16th largest by enrollment, is the only one that started in 2009, is one of 7 in phase 3, and was the 17th registered.

Multiple Sclerosis

3,271 studies on the registry are indexed under Multiple Sclerosis; 663 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

None of the 34 studies testing Interferon beta-1a in Multiple Sclerosis is open now. The open studies under Multiple Sclerosis, anywhere →

About Interferon beta-1a

Interferon beta-1a: first FDA approval 1996 (AVONEX), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 431 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 212 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 34 studies testing Interferon beta-1a in Multiple Sclerosis as a file.
02

Study summary

The primary objective of the study was to evaluate the safe and effective use of the single-use autoinjector for the intramuscular (IM) delivery of liquid Avonex® (interferon beta-1a) in participants with multiple sclerosis (MS).

Read the detailed description

The Main Study was a 4-week treatment period which consisted of 1 Avonex manual injection using a prefilled syringe, followed by 3 Avonex injections using the single-use autoinjector. The Extension Study was designed to provide continuation of treatment with the Avonex single-use autoinjector to eligible participants who completed the Main Study for up to an additional 12 weeks, and to obtain additional safety and preference data for the Avonex single-use autoinjector.

Participants were enrolled under the initial study protocol (Initial Subject Subset); the study was subsequently suspended. Changes were made to the protocol (including modifications to the autoinjector needle), and additional participants were enrolled (Main Subject Subset).

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ability to understand the purpose and risks of the study and provide signed and dated and authorization to use protected health information (PHI) in accordance with national and local subject privacy regulations.
  2. Must be 18 to 65 years old, inclusive, at the time of informed consent.
  3. Must currently be self-administering Avonex Prefilled Syringes to treat MS and must have been self-administering Avonex Prefilled Syringes for the 12 weeks prior to the Screening Visit.
  4. In the investigator's opinion, subjects must be willing and able to self-administer all injections required by the protocol.
  5. Must speak English.
  6. All male subjects and female subjects of must practice effective during the study.

Exclusion criteria

Exclusion Criteria:

  1. History of seizure disorder or unexplained blackouts OR history of a seizure within 3 months prior to the Screening Visit.
  2. History of suicidal ideation within 3 months prior to Day 1 or an episode of severe depression within 3 months prior to Day 1. Severe depression is defined as any episode of depression that requires hospitalization, or the initiation of antidepressant therapy, or an increase in the dose of an existing regimen of antidepressant therapy. NOTE: Subjects receiving ongoing antidepressant therapy are not excluded from the study unless the dose has been increased within the 3 months prior to the Screening Visit.
  3. local infection (for example cellulitis, abscess) or systemic infection (pneumonia, septicemia), at the discretion of the Investigator.
  4. Known history of (HIV).
  5. Known history of, or positive test result for virus (test for hepatitis C virus antibody [HCV Ab]) or virus (test for Hepatitis B Surface Antigen [HBsAg] and/or Hepatitis B Core Antibody [HBcAb]).
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
95 participants (actual)

Study arms

  • Experimental
    Avonex Single-Use Autoinjector

    Participants received open label weekly treatment with Avonex 30 mcg intramuscular (IM) injections, provided in Avonex prefilled syringes. In the Main Study, injection #1: administration of Avonex prefilled syringe via manual IM injection on Day 1. Injections #2, #3, and #4: administration of Avonex prefilled syringe using the single-use autoinjector on Days 8, 15, and 22, respectively. In the Extension Study, participants were to continue treatment with the Avonex single-use autoinjector for up to an additional 12 weeks.

    Device: single-use autoinjector with a prefilled liquid Avonex syringe · Device: Avonex prefilled syringe via manual IM injection · Drug: BG9418 (interferon beta-1a)

Interventions

  • Devicesingle-use autoinjector with a prefilled liquid Avonex syringe
  • DeviceAvonex prefilled syringe via manual IM injection
  • Also known as: Avonex

06

What researchers measure

Primary outcomes

  1. Percentage of Participants in the Main Subset With Overall Success Using the Avonex Single-Use Autoinjector

    A trainer/observer documented the participant's ability to self-inject with the Avonex single-use autoinjector and completed an observation form. Overall success in using the device for each participant was defined as no failures occurring in any step (ie, device set-up, self-administration of injection, and capping/disposal of the device) during the participant's use of the single-use Avonex autoinjector.

    Time frame: Day 22

Other outcomes

  1. Number of Participants in the Initial Subset Who Were Satisfied With the Avonex Single-Use Autoinjector

    Number of participants in the Initial Subset who answered yes to the question "Were you satisfied with this single-use injector?" on the Subject Satisfaction Questionnaire.

    Time frame: Day 23

  2. Percentage of Participants With No Erythema, Induration, or Tenderness, and Normal Temperature at the Injection Site After Injection With the Avonex Single-use Autoinjector

    The clinician/investigator evaluated the injection site for erythema, induration, and tenderness as none, mild, moderate, or severe after the use of the Avonex single-use autoinjector. Temperature at the injection site was evaluated as normal, warm, or hot. Those participants having no erythema, induration, or tenderness, and normal temperature at the injection site after injection are presented.

    Time frame: Day 1, Day 8 through 22 (highest severity reported between Days 8 and 22)

  3. Mean Score for Ease of Use Grading Scale

    Participants scored the ease of use of the Avonex manual injector (Day 1) and single-use autoinjector (Days 8, 15, 22) using a scale that ranged from 0 (extremely difficult) to 10 (extremely easy).

    Time frame: Day 1, Day 8, Day 15, Day 22

  4. Percentage of Participants Who Rated the Avonex Single-use Autoinjector Printed and DVD Training Materials as Very Effective

    Participants evaluated how effective the printed and DVD instructions were in educating how to use the Avonex single-use autoinjector. Participants could choose one of the following descriptive answers: not effective at all, somewhat ineffective, neutral, somewhat effective, or very effective.

    Time frame: Day 8, Day 15, Day 22

  5. Mean Score for Initial Subset on Autoinjector Instructions Grading Scale

    Participants in the Initial Subset were asked to answer the question "How satisfied are you with the presentation of the autoinjector instructions?" on a rating scale of 0 (extremely dissatisfied) to 10 (extremely satisfied).

    Time frame: Day 8

  6. Percentage of Participants Who Indicated No Difficulty With the Injection Procedure of the Manual Injection or the Avonex Single-use Autoinjector

    Participants assessed whether they had experienced any difficulty with the procedure in preparing, injecting, removing, and disposing process after each injection with the Avonex single-use autoinjector by answering yes or no to the following question: "Did you have any difficulty with your injection?" The percentage of participants answering no to this question for both the manual injection on Day 1 and the autoinjector on Days 8. 15 and 22 are presented.

    Time frame: Day 1, Day 8, Day 15, Day 22

  7. Percentage of Participants Who Indicated a Preference for the Avonex Single-use Autoinjector Over the Manual Avonex Prefilled Syringe

    Participants were asked whether they preferred using the Avonex single-use autoinjector over the manual Avonex prefilled syringe. Preference was defined as participants answering yes to the following question: Do you prefer this single-use autoinjector over the manual injection?

    Time frame: Day 23

  8. Mean Pain Score After Injection

    Participants scored their pain level after the use of the manual prefilled syringe on Day 1 and the Avonex single-use autoinjector on Days 8, 15, and 22 on a scale ranging from 0 (no pain) to 10 (extremely painful).

    Time frame: Day 1, Day 8, Day 15, Day 22

07

Results

Posted Aug 9, 2011
Limitations and caveats
The Initial Subset is too small a population from which to draw conclusions.

Participant flow

Recruitment occurred in the following stages: Main Study (Initial Subset and Main Subset enrolled), and Extension Study. Initial subset participants were withdrawn when the study was suspended. After a protocol amendment, the Main Subset participants were enrolled. Only those in the Main Subset had the option to participate in the Extension Study.

Main Study: Prior to Study Suspension
Participant flow — Main Study: Prior to Study Suspension
MilestoneAvonex Single-Use Autoinjector: Initial SubsetAvonex Single-Use Autoinjector: Main Subset
Started210
Completed manual injection210
Continued with autoinjector injections190
Completed70
Not completed140
Withdrew: Adverse event10
Withdrew: Subject was withdrawn20
Withdrew: Study suspension110
Main Study: After Study Restart
Participant flow — Main Study: After Study Restart
MilestoneAvonex Single-Use Autoinjector: Initial SubsetAvonex Single-Use Autoinjector: Main Subset
Started074
Completed manual injection074
Continued with autoinjector injections072
Completed071
Not completed03
Withdrew: Adverse event02
Withdrew: Noncompliance01
Extension Study
Participant flow — Extension Study
MilestoneAvonex Single-Use Autoinjector: Initial SubsetAvonex Single-Use Autoinjector: Main Subset
Started064
Completed061
Not completed03
Withdrew: Lost to follow-up01
Withdrew: Physician decision02

Outcome measures

PrimaryPercentage of Participants in the Main Subset With Overall Success Using the Avonex Single-Use Autoinjector

A trainer/observer documented the participant's ability to self-inject with the Avonex single-use autoinjector and completed an observation form. Overall success in using the device for each participant was defined as no failures occurring in any step (ie, device set-up, self-administration of injection, and capping/disposal of the device) during the participant's use of the single-use Avonex autoinjector.

Time frame:
Day 22
Reported as:
Number · percentage of participants
Percentage of Participants in the Main Subset With Overall Success Using the Avonex Single-Use Autoinjector
percentage of participantsAvonex Single-Use Autoinjector: Main Subset
Percentage of Participants in the Main Subset With Overall Success Using the Avonex Single-Use Autoinjector89 (81 to 96)
Other pre-specifiedNumber of Participants in the Initial Subset Who Were Satisfied With the Avonex Single-Use Autoinjector

Number of participants in the Initial Subset who answered yes to the question "Were you satisfied with this single-use injector?" on the Subject Satisfaction Questionnaire.

Time frame:
Day 23
Reported as:
Number · participants
Number of Participants in the Initial Subset Who Were Satisfied With the Avonex Single-Use Autoinjector
participantsAvonex Single-Use Autoinjector: Initial Subset
Number of Participants in the Initial Subset Who Were Satisfied With the Avonex Single-Use Autoinjector14
Other pre-specifiedPercentage of Participants With No Erythema, Induration, or Tenderness, and Normal Temperature at the Injection Site After Injection With the Avonex Single-use Autoinjector

The clinician/investigator evaluated the injection site for erythema, induration, and tenderness as none, mild, moderate, or severe after the use of the Avonex single-use autoinjector. Temperature at the injection site was evaluated as normal, warm, or hot. Those participants having no erythema, induration, or tenderness, and normal temperature at the injection site after injection are presented.

Time frame:
Day 1, Day 8 through 22 (highest severity reported between Days 8 and 22)
Reported as:
Number · percentage of participants
Percentage of Participants With No Erythema, Induration, or Tenderness, and Normal Temperature at the Injection Site After Injection With the Avonex Single-use Autoinjector
percentage of participantsAvonex Single-Use Autoinjector: Main SubsetAvonex Single-Use Autoinjector: Initial Subset
No Erythema6595
No Induration86100
No Tenderness9079
Normal Temperature100100
Other pre-specifiedMean Score for Ease of Use Grading Scale

Participants scored the ease of use of the Avonex manual injector (Day 1) and single-use autoinjector (Days 8, 15, 22) using a scale that ranged from 0 (extremely difficult) to 10 (extremely easy).

Time frame:
Day 1, Day 8, Day 15, Day 22
Reported as:
Mean · scores on a scale
Mean Score for Ease of Use Grading Scale
scores on a scaleAvonex Single-Use Autoinjector: Main SubsetAvonex Single-Use Autoinjector: Initial Subset
Day 1 (Manual Injection) n=72, 198.1 ± 2.647.4 ± 2.41
Day 8 (Autoinjector) n= 72, 188.9 ± 1.966.8 ± 3.39
Day 15 (Autoinjector) n=71, 168.7 ± 2.476.7 ± 3.07
Day 22 (Autoinjector) n=70, 79.3 ± 1.875.9 ± 3.13
Other pre-specifiedPercentage of Participants Who Rated the Avonex Single-use Autoinjector Printed and DVD Training Materials as Very Effective

Participants evaluated how effective the printed and DVD instructions were in educating how to use the Avonex single-use autoinjector. Participants could choose one of the following descriptive answers: not effective at all, somewhat ineffective, neutral, somewhat effective, or very effective.

Time frame:
Day 8, Day 15, Day 22
Reported as:
Number · percentage of participants
Percentage of Participants Who Rated the Avonex Single-use Autoinjector Printed and DVD Training Materials as Very Effective
percentage of participantsAvonex Single-Use Autoinjector: Main Subset
Printed instructions, Day 8; n=6893
DVD, Day 8; n=6988
Printed instructions, Day 15; n=4290
DVD, Day 15; n=1090
Printed instructions, Day 22; n=2492
DVD, Day 22; n=989
Other pre-specifiedMean Score for Initial Subset on Autoinjector Instructions Grading Scale

Participants in the Initial Subset were asked to answer the question "How satisfied are you with the presentation of the autoinjector instructions?" on a rating scale of 0 (extremely dissatisfied) to 10 (extremely satisfied).

Time frame:
Day 8
Reported as:
Mean · scores on a scale
Mean Score for Initial Subset on Autoinjector Instructions Grading Scale
scores on a scaleAvonex Single-Use Autoinjector: Initial Subset
Mean Score for Initial Subset on Autoinjector Instructions Grading Scale9.5 ± 0.71
Other pre-specifiedPercentage of Participants Who Indicated No Difficulty With the Injection Procedure of the Manual Injection or the Avonex Single-use Autoinjector

Participants assessed whether they had experienced any difficulty with the procedure in preparing, injecting, removing, and disposing process after each injection with the Avonex single-use autoinjector by answering yes or no to the following question: "Did you have any difficulty with your injection?" The percentage of participants answering no to this question for both the manual injection on Day 1 and the autoinjector on Days 8. 15 and 22 are presented.

Time frame:
Day 1, Day 8, Day 15, Day 22
Reported as:
Number · percentage of participants
Percentage of Participants Who Indicated No Difficulty With the Injection Procedure of the Manual Injection or the Avonex Single-use Autoinjector
percentage of participantsAvonex Single-Use Autoinjector: Main Subset
Day 1 (Manual Injection); n=7089
Day 8 (Autoinjector); n=7190
Day 15 (Autoinjector); n=7190
Day 22 (Autoinjector); n=7190
Other pre-specifiedPercentage of Participants Who Indicated a Preference for the Avonex Single-use Autoinjector Over the Manual Avonex Prefilled Syringe

Participants were asked whether they preferred using the Avonex single-use autoinjector over the manual Avonex prefilled syringe. Preference was defined as participants answering yes to the following question: Do you prefer this single-use autoinjector over the manual injection?

Time frame:
Day 23
Reported as:
Number · percentage of participants
Percentage of Participants Who Indicated a Preference for the Avonex Single-use Autoinjector Over the Manual Avonex Prefilled Syringe
percentage of participantsAvonex Single-Use Autoinjector: Main SubsetAvonex Single-Use Autoinjector: Initial Subset
Percentage of Participants Who Indicated a Preference for the Avonex Single-use Autoinjector Over the Manual Avonex Prefilled Syringe9453
Other pre-specifiedMean Pain Score After Injection

Participants scored their pain level after the use of the manual prefilled syringe on Day 1 and the Avonex single-use autoinjector on Days 8, 15, and 22 on a scale ranging from 0 (no pain) to 10 (extremely painful).

Time frame:
Day 1, Day 8, Day 15, Day 22
Reported as:
Mean · scores on a scale
Mean Pain Score After Injection
scores on a scaleAvonex Single-Use Autoinjector: Main SubsetAvonex Single-Use Autoinjector: Initial Subset
Day 1 (Manual Injection) n=72, 191.7 ± 1.762.5 ± 2.87
Day 8 (Autoinjector) n= 72, 181.0 ± 1.461.9 ± 2.19
Day 15 (Autoinjector) n=71, 161.3 ± 1.642.1 ± 1.95
Day 22 (Autoinjector) n=70, 70.7 ± 1.132.4 ± 2.99

Adverse events

Collected over Adverse events (AEs) and serious adverse events (SAEs) treatment-emergent to the autoinjector (from Day 8) through Day 23 (end of Main Study, for the Initial Study Subset), and through Day 107 (end of Extension Period, for the Main Study Subset).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Avonex Single-Use Autoinjector: Main Subset—0/72 (0%)33/72 (45.8%)
Avonex Single-Use Autoinjector: Initial Subset—0/19 (0%)7/19 (36.8%)
Most frequent other events
Showing 10 of 49
Most frequent other events
EventAvonex Single-Use Autoinjector: Main SubsetAvonex Single-Use Autoinjector: Initial Subset
Injection Site PainGeneral disorders7/724/19
Injection Site HaematomaGeneral disorders6/721/19
HypoaesthesiaNervous system disorders2/721/19
HeadacheNervous system disorders1/721/19
Nasal CongestionRespiratory, thoracic and mediastinal disorders2/721/19
NauseaGastrointestinal disorders1/721/19
Pain In ExtremityMusculoskeletal and connective tissue disorders1/721/19
Influenza Like IllnessGeneral disorders3/721/19
Injection Site ErythemaGeneral disorders3/721/19
PruritisSkin and subcutaneous tissue disorders0/721/19

Baseline characteristics

This table presents the baseline characteristics for both the Initial Subset and Main Subset populations. As represented in the Participant Flow module, these 2 groups participated prior to and after study suspension, respectively; therefore the total column should not be interpreted as cumulative.

Age, Categorical
Age, Categorical(Participants)Avonex Single-Use Autoinjector: Main SubsetAvonex Single-Use Autoinjector: Initial SubsetTotal
<=18 years000
Between 18 and 65 years722193
>=65 years202
Sex: Female, Male
Sex: Female, Male(Participants)Avonex Single-Use Autoinjector: Main SubsetAvonex Single-Use Autoinjector: Initial SubsetTotal
Female641882
Male10313
08

Study locations

16 sites
  • Research Site
    Gilbert, Arizona 85234, United States
  • Research Site
    Phoenix, Arizona 85018, United States
  • Research Site
    Maitland, Florida 32751, United States
  • Research Site
    Atlanta, Georgia 30327, United States
  • Fort Wayne Neurological Center
    Fort Wayne, Indiana 46804, United States
  • Research Site
    Boston, Massachusetts 2135, United States
  • Michigan Institute for Neurological Disorders
    Farmington Hills, Michigan 28595, United States
  • Research Site
    Buffalo, New York 14203, United States
  • Comprehensive Multiple Sclerosis Care Center
    Patchogue, New York 11772, United States
  • Research Site
    Charlotte, North Carolina 28207, United States
  • Neurology & Neuroscience Associates, Inc.
    Akron, Ohio 4320, United States
  • Research Site
    Dallas, Texas 75214, United States
  • Research Site
    Round Rock, Texas 78681, United States
  • Research Site
    Salt Lake City, Utah 84103, United States
  • Research Site
    Richmond, Virginia 23298, United States
  • Research Site
    Charleston, West Virginia 25301, United States
09

References and documents

Publications

  • Phillips JT, Fox E, Grainger W, Tuccillo D, Liu S, Deykin A. An open-label, multicenter study to evaluate the safe and effective use of the single-use autoinjector with an Avonex(R) prefilled syringe in multiple sclerosis subjects. BMC Neurol. 2011 Oct 14;11:126. doi: 10.1186/1471-2377-11-126. PubMed 21999176 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2009, a primary completion of Jul 2010 and a completion of Oct 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2011, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2009
First posted
Jan 23, 2009
Start
Jan 2009
Primary completionActual
Jul 2010
CompletionActual
Oct 2010
Results first posted
Aug 9, 2011
Last update
Jun 3, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00828204
Lead sponsor
Biogen
Responsible party
Sponsor
First posted
Jan 23, 2009
Start date
Jan 2009
Primary completion
Jul 2010
Completion
Oct 2010
Results posted
Aug 9, 2011
Last update
Jun 3, 2014

Study contacts

Medical Director
study director · Biogen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Interferon beta-1a

Start the discussion